26343 Blastomyces Antibody, Enzyme Immunoassay, Serum (BLAST)

​Blastomycosis, Fungal Serology

​Aiding in the diagnosis of blastomycosis

Gross Hemolysis

Gross Lipemia

Heat inactivated specimen

​A negative result does not rule-out blastomycosis.

Cross-reactivity may occur with other fungal infections such as Aspergillus, Coccidioides, or Histoplasma.

​Blastomyces dermatitidis, an adimorphic fungus, is endemic throughout the Midwestern, south-central, and southeastern Unites States, particularly in regions around the Ohio and Mississippi river valley, the Great Lakes and the Saint Lawrence River. It is also found in regions of Canada. Blastomyces is an environmental fungus, preferring moist soil and decomposing organic matter, which produces fungal spores that are released and inhaled by animals or humans. At body temperature, the spores mature into yeast, which can stay in the lungs or disseminate through the bloodstream to other parts of the body. Recently, through phylogenetic analysis, Blastomyces dermatitidis has been separated into two distinct species; B. dermatitidis and Blastomyces gilchristii, both able to cause blastomycosis in infected patients. Interestingly, B. dermatitidis infections are associated more frequently with dissemination, particularly in elderly patients, smokers and immunocompromised hosts, while B. gilchristii has primarily been associated with pulmonary and constitutional symptoms.

Approximately 50% of patients infected with Blastomyces will develop symptoms, which are frequently non-specific and, include fever, cough, night sweats, myalgia or arthralgia, weight loss, chest pain and fatigue. Typically symptoms appear anywhere from 3 weeks to 3 months following infection.

Diagnosis of blastomycosis relies on a combination of assays, including culture and molecular testing on appropriate specimens and serologic evaluation for both antibodies to and antigen released from Blastomyces. Although culture remains the gold standard method and is highly specific, the organism can take several days to weeks to grow, and sensitivity is diminished in cases of acute or localized disease. Similarly, molecular testing offers high specificity and a rapid turnaround time, however, sensitivity is imperfect. Detection of an antibody response to Blastomyces offers high specificity, however, results may be falsely negative in acutely infected patients and in immunosuppressed patients.

​A positive result indicates that IgG and/or IgM antibodies to Blastomyces were detected. The presence of antibodies is presumptive evidence that the patient was or is currently infected with (or was exposed to) Blastomyces.

A negative result indicates that antibodies to Blastomyces were not detected. The absence of antibodies is presumptive evidence that the patient was not infected with Blastomyces. However, the specimen may have been obtained before antibodies were detectable or the patient may be immunosuppressed. If infection is suspected, another specimen should be collected 7 to 14 days later and submitted for testing.

Specimens testing positive or equivocal will be submitted for further testing by another conventional serologic test (eg, SBL / Blastomyces Antibody by Immunodiffusion, Serum).